Hopes rise for male contraceptive pill breakthroughTim Dune
Hopes rise for male contraceptive pill breakthrough
Hopes for a male contraceptive pill have increased after a trial showed a once-daily capsule appeared to work with no significant side-effects.
The drug aims to suppress levels of hormones that drive the production of sperm and testosterone in the testes.
In the month-long study, doctors found that levels of the hormones required for sperm production fell in men who took the daily capsule, suggesting their sperm counts had been markedly reduced. The next step will be to confirm the fall and determine if it is sufficient.
Stephanie Page, a professor of medicine and co-senior investigator on the trial at the University of Washington in Seattle, said: “The goal is to expand contraceptive options and create a menu of choices for men like we have for women. We are neglecting a major potential user population with the limited options currently available to men.”
Despite the range of contraceptive pills, patches and injections available for women, and the choice of either condoms or vasectomies for men, the rate of unplanned pregnancies had stagnated at about 40%, Page said.
Forty healthy men enrolled in the phase one safety trial at the University of Washington and LA BioMed. Ten volunteers received a placebo capsule; the rest were assigned a 200mg or 400mg dose of the drug, 11-beta-MNTDC. All took one capsule daily with food for 28 days, according to a presentation at the Endocrine Society’s annual conference in New Orleans.
Page said: “Since testosterone production is shut down in the testes, the androgen action in the rest of the body maintains ‘maleness’ elsewhere, supporting things like male pattern hair, deep voice, sex drive and function, and lean body mass.”
Men who took the drug had substantially lower levels of LH and FSH compared with those who had the placebo, suggesting the drug had stopped their sperm production.
Christina Wang, a co-senior investigator on the trial at LA BioMed, said the next step was to measure the fall in sperm production directly. “This study is very short and we need three months if not more to stop sperm production,” she said. “All we have shown so far is that it shuts down the hormones that control the function of the testes.”
While none of the men dropped out or had less sex during the trial, some experienced mild side-effects. Four to six men reported either headaches, fatigue or acne, five experienced a mildly decreased libido, and two had mild erectile dysfunction. Similar side-effects have hampered other experimental male contraceptives. In the latest trial, some men also put on weight, Wang said.
The researchers say it could be a decade before a male pill is on the market, but they believe there is strong demand from couples. “Men have really limited options when it comes to reversible contraception,” Wang said. “When we ask men about hormonal compounds, about 50% are willing to try this new method. And when you ask their partners, the percentage is even higher.”
Creative Commons Disclosure
About The Mandatory Training Group
The Mandatory Training Group is the leading provider of accredited mandatory and statutory health and social care courses for healthcare professionals across the UK regions.
We intend to provide CQC compliant courses to help doctors, nurses, carers, care providers and staff deliver safe, effective, patient-centred and high-quality care to its service users at all times. Click on the links below to learn more on our online training and classroom-based courses:
- CSTF Aligned Drug Calculations & Dosage training
- CQC Compliant Safe Handling of Medication Training
- CQC Compliant Statutory & Mandatory Training for Healthcare Professionals
- Statutory & Mandatory Training Courses for Health & Social Care Workers
- Mandatory & Statutory Training Courses for Health Care & Social Care Providers
- Accredited Health & Safety Mandatory Training Courses
Contact our Support Team on 02476100090 or via Email for more courses relating to workplace improvement and productivity.